BeiGene Grants Share Options to INEDs Under 2016 Plan

The latest announcement is out from BeiGene Ltd ( (HK:6160) ).

BeiGene, Ltd. announced the grant of share options and restricted share units to nine independent non-executive directors (INEDs) under its 2016 Share Option and Incentive Plan. The grants, which involve a total of 15,750 American Depositary Shares (ADSs) for options and 7,605 ADSs for restricted share units, are part of the compensation package for INEDs. This initiative aims to align the directors’ interests with the company’s long-term strategy and development, motivating them to contribute effectively to the company’s growth. The options have a ten-year validity period and are subject to accelerated vesting under certain conditions, reflecting the company’s commitment to retaining and incentivizing key personnel.

The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.

More about BeiGene Ltd

BeiGene, Ltd. is a biotechnology company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative cancer therapies. The company is committed to improving treatment outcomes for cancer patients worldwide through its research and development efforts.

Average Trading Volume: 6,775,337

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$236.3B

Learn more about 6160 stock on TipRanks’ Stock Analysis page.